MYC and breast cancer: In vitro studies with HSB‐510 have demonstrated substantial growth inhibition of breast cancer cell lines, MDA‐MB‐468, SUM‐149, MCF‐7, and Ehrlich ascites carcinoma (EAC) as well as downregulation of phospho‐AKT, phospho‐ERK, and c‐Myc levels.